Pitavastatin Further Decreases Serum High-Sensitive C-Reactive Protein Levels in Hypertensive Patients with Hypercholesterolemia Treated with Angiotensin II, Type-1 Receptor Antagonists

REFERENCES

• Yoshino G. Metabolic syndrome and small dense LDL. Rinsho Byori 2006;54:1247–1256.
   PubMedGoogle Scholar
• Matsubara K, Yamamoto Y, Sonoyama K, Igawa G, Furuse M, Yatsuhashi T, Hamada T, Ogino K, Igawa O, Hisatome I, Shigemasa C. Current status of lipid management of hypertensive patients. Hypertens Res 2003;26:699–704.
   PubMed Web of Science ®Google Scholar
• Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergen J. ASCOT investigators; Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 2003;361:1149–1158.
   PubMed Web of Science ®Google Scholar
• Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362:801–809.
   PubMed Web of Science ®Google Scholar
• Okazaki S, Yokoyama T, Miyauchi K, Shimada K, Kurata T, Sato H, Daida H. Early statin treatment in patients with acute coronary syndrome: Demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: The ESTABLISH Study. Circulation 2004;110:1061–1068.
   PubMed Web of Science ®Google Scholar
• Naya M, Tsukamoto T, Morita K, Katoh C, Furumoto T, Fujii S, Tamaki N, Tsutsui H. Plasma interleukin-6 and tumor necrosis factor-alpha can predict coronary endothelial dysfunction in hypertensive patients. Hypertens Res 2007;30:541–548.
   PubMed Web of Science ®Google Scholar
• Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res 2001; 89:763–771.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E. Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 (PROVE IT-TIMI 22) investigators; C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20–28.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001;103:1191–1193.
   PubMed Web of Science ®Google Scholar
• Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study. JAMA 2001;286:64–70.
   PubMed Web of Science ®Google Scholar
• Plenge JK, Hernandez TL, Weil KM, Poirier P, Grunwald GK, Marcovina SM, Eckel RH. Simvastatin lowers C-reactive protein within 14 days: An effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002;106:1447–1452.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestqaard BG, Shepherd J, Willerson JT, Glynn RJ, JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195–2207.
   PubMed Web of Science ®Google Scholar
• Prasad K. C-reactive protein (CRP)-lowering agents. Cardiocasc Drug Rev 2006;24:33–50.
   PubMed Web of Science ®Google Scholar
• Fliser D, Buchhloz K, Haller H. European Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators. Anti-inflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004;110:1103–1107.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Rifai N, Glynn RJ, Val-MARC Investigators. Valsartan, blood pressure reduction, and C‐reactive protein: primary report of the Val-MARC trial. Hypertension 2006;48:73–79.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Tuzcu EM, Sipahi I, Grasso AW, Schoenhagen P, Hu T, Wolski K, Crowe T, Desai MY, Hazen SL, Kapadia SR, Nissen SE. statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007;297:499–508.
   PubMed Web of Science ®Google Scholar
• Pearson TA, Mensah, GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC, Taubert K, Tracy RP, Vinicor F. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107: 499–511.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Obata JE, Kitta Y, Takano H, Kobayashi T, Fujioka D, Saito Y, Kodama Y, Kawabata K, Mende A, Yano T, Hirano M, Sano K, Nakamura K, Kugiyama K. Rapid stabilization of vulnerable carotid plaque within 1 month of pitavastatin treatment in patients with acute coronary syndrome. J Cardiovasc Phamacol 2008;51:365–371.
   PubMed Web of Science ®Google Scholar
• Robinson JG. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk. Am J Cardiol 2008;101:1009–1015.
   PubMed Web of Science ®Google Scholar
• Arnaud C, Veillard NR, Mach F. Cholesterol-independent effects of statins in inflammation, immunomodulation and atherosclerosis. Curr Drug Targets Cardiovasc Haematol Disord 2005;5:127–134.
   PubMedGoogle Scholar
• Alegret M, Silvestre JS. Pleiotropic effects of statins and related pharmacological experimental approaches. Methods Find Exp Clin Pharmacol 2006;28:627–656.
   PubMed Web of Science ®Google Scholar
• Vasankari T, Ahotupa M, Toikka J, Mikkola J, Irjala K, Pasanen P, Neuvonen K, Raitakari O, Viikari J. Oxidized LDL and thickness of carotid intima-media are associated with coronary atherosclerosis in middle-aged men: lower levels of oxidized LDL with statin therapy. Atherosclerosis 2001;155:403–412.
   PubMed Web of Science ®Google Scholar
• Liao JK. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 2005:96:24F–33F.
   PubMed Web of Science ®Google Scholar
• Gelosa P, Cimino M, Pignieri A, Tremoli E, Guerrini U, Sironi L. The role of HMG-CoA reductase inhibition in endothelial dysfunction and inflammation. Vasc Health Risk Manag 2007;3:567–577.
   PubMedGoogle Scholar
• Algret M, Silvestre JS. Pleiotropic effects of statins and related pharmacological experimental approaches. Methods Find Exp Clin Pharmacol 2006;28:627–656.
   PubMed Web of Science ®Google Scholar
• Wang J, Tokoro T, Matsui K, Higa S, Kitajima I. Pitavastatin at low dose activates endothelial nitric oxide synthase through PI3K-AKT pathway in endothelial cells. Life Sci 2005;76:2257–2268.
   PubMed Web of Science ®Google Scholar
• Jialal I, Devaraj S, Venugopal SK. C-reactive protein: risk marker or mediator in athero- thrombosis? Hypertension 2004;44:6–11.
   PubMed Web of Science ®Google Scholar
• Liang YJ, Shyu KG, Wang BW, Lai LP. Simvastatin inhibits C-reactive protein-induced pro-inflammatory changes in endothelial cells by decreasing mevalonate pathway products. Cardiology 2008;110:182–190.
   PubMed Web of Science ®Google Scholar
• Hu WL, Qian SB, Li JJ. Decreased C-reactive protein-induced resistin production in human monocytes by simvastatin. Cytokine 2007;40:201–206.
   PubMed Web of Science ®Google Scholar
• Kibayashi E, Urakaza M, Kobashi C, Kishida M, Takata M, Sato A, Yamazaki K, Kobayashi M. Inhibitory effect of pitavastatin (NK-104) on the C-reactive-protein-induced interleu- kin-8 production in human aortic endothelial cells. Clin Sci (Lond) 2005;108:515–521.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Kobayashi H, Sato F, Yonemitsu Y, Sueishi K. Plaque-stabilizing effect of pitavastatin in Watanabe heritable hyperlipidemic (WHHL) rabbits. J Atheroscler Thromb 2003;10:45–50.
   Google Scholar